questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Glycosyltransferase
Pentosyltransferases
ADP ribose transferases
ADP ribose transferases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Marqueurs biologiques
ADP-ribose
Tests enzymatiques
Enzymes
Réparation de l'ADN
Troubles métaboliques
Imagerie médicale
Enzymes
Symptômes
5
Maladies neurodégénératives
Cancer
Troubles cognitifs
Mémoire
Enzymes
Variabilité des symptômes
Anomalies cutanées
Troubles métaboliques
Asymptomatique
Dysfonction enzymatique
Prévention
5
Prévention
Mode de vie sain
Exercice physique
Santé cellulaire
Traitements
5
Thérapie génique
Médicaments ciblés
Essais cliniques
Inhibiteurs
Médecine personnalisée
Dysfonctionnement enzymatique
Gestion des symptômes
Traitements
Complications
5
Cancers
Maladies auto-immunes
Maladies cardiovasculaires
Dysfonctionnement enzymatique
Qualité de vie
Complications
Antécédents médicaux
Prévisibilité
Facteurs de risque
5
Facteurs génétiques
Toxines
Vieillissement
Facteurs de risque
Antécédents familiaux
Risque
Alimentation
Antioxydants
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "ADP ribose transferases : Questions médicales les plus fréquentes",
"headline": "ADP ribose transferases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les ADP ribose transferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pentosyltransferases",
"url": "https://questionsmedicales.fr/mesh/D010430",
"about": {
"@type": "MedicalCondition",
"name": "Pentosyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D010430",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NAD nucleosidase",
"alternateName": "NAD+ Nucleosidase",
"url": "https://questionsmedicales.fr/mesh/D009244",
"about": {
"@type": "MedicalCondition",
"name": "NAD nucleosidase",
"code": {
"@type": "MedicalCode",
"code": "D009244",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "ADP-ribosyl cyclase",
"alternateName": "ADP-ribosyl Cyclase",
"url": "https://questionsmedicales.fr/mesh/D036541",
"about": {
"@type": "MedicalCondition",
"name": "ADP-ribosyl cyclase",
"code": {
"@type": "MedicalCode",
"code": "D036541",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660.060"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Poly(ADP-ribose) polymerases",
"alternateName": "Poly(ADP-ribose) Polymerases",
"url": "https://questionsmedicales.fr/mesh/D011065",
"about": {
"@type": "MedicalCondition",
"name": "Poly(ADP-ribose) polymerases",
"code": {
"@type": "MedicalCode",
"code": "D011065",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Poly (ADP-Ribose) polymerase-1",
"alternateName": "Poly (ADP-Ribose) Polymerase-1",
"url": "https://questionsmedicales.fr/mesh/D000071137",
"about": {
"@type": "MedicalCondition",
"name": "Poly (ADP-Ribose) polymerase-1",
"code": {
"@type": "MedicalCode",
"code": "D000071137",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.420"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tankyrases",
"alternateName": "Tankyrases",
"url": "https://questionsmedicales.fr/mesh/D038501",
"about": {
"@type": "MedicalCondition",
"name": "Tankyrases",
"code": {
"@type": "MedicalCode",
"code": "D038501",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.840"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases",
"alternateName": "ADP Ribose Transferases",
"code": {
"@type": "MedicalCode",
"code": "D036002",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anthony K L Leung",
"url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Morgan Dasovich",
"url": "https://questionsmedicales.fr/author/Morgan%20Dasovich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Mohsen Badiee",
"url": "https://questionsmedicales.fr/author/Mohsen%20Badiee",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205."
}
},
{
"@type": "Person",
"name": "Yong Zhang",
"url": "https://questionsmedicales.fr/author/Yong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States."
}
},
{
"@type": "Person",
"name": "Sua Myong",
"url": "https://questionsmedicales.fr/author/Sua%20Myong",
"affiliation": {
"@type": "Organization",
"name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The relevance of EGFR, ErbB receptors and neuregulins in human adipocytes and adipose tissue in obesity.",
"datePublished": "2022-11-09",
"url": "https://questionsmedicales.fr/article/36411648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2022.113972"
}
},
{
"@type": "ScholarlyArticle",
"name": "Non-equilibrium modalities of inhibition: Characterizing irreversible inhibition for the ErbB receptor family members.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37858541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.mie.2023.08.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulation of ErbB Receptors by the Ca",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36979639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biomedicines11030661"
}
},
{
"@type": "ScholarlyArticle",
"name": "iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells.",
"datePublished": "2022-09-08",
"url": "https://questionsmedicales.fr/article/35971826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/jcs.259949"
}
},
{
"@type": "ScholarlyArticle",
"name": "Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35667295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.oraloncology.2022.105939"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosyltransferase",
"item": "https://questionsmedicales.fr/mesh/D016695"
},
{
"@type": "ListItem",
"position": 6,
"name": "Pentosyltransferases",
"item": "https://questionsmedicales.fr/mesh/D010430"
},
{
"@type": "ListItem",
"position": 7,
"name": "ADP ribose transferases",
"item": "https://questionsmedicales.fr/mesh/D036002"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : ADP ribose transferases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur ADP ribose transferases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur ADP ribose transferases",
"description": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?\nQuels marqueurs biochimiques sont associés aux ADP ribose transferases ?\nY a-t-il des tests spécifiques pour les ADP ribose transferases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests d'imagerie sont-ils utiles pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur ADP ribose transferases",
"description": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?\nPeut-on observer des symptômes neurologiques ?\nLes symptômes varient-ils selon le type d'enzyme ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes sont-ils toujours présents ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur ADP ribose transferases",
"description": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir ces dysfonctionnements ?\nLes vaccinations ont-elles un rôle préventif ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur ADP ribose transferases",
"description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes suppléments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils curatifs ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur ADP ribose transferases",
"description": "Quelles complications peuvent survenir avec ces dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies cardiovasculaires ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur ADP ribose transferases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe stress a-t-il un impact sur ces enzymes ?\nLes antécédents familiaux influencent-ils le risque ?\nL'alimentation joue-t-elle un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=ErbB+Receptors#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour évaluer leur activité."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux ADP ribose transferases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'ADP-ribose libre et de protéines modifiées peuvent servir de marqueurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour les ADP ribose transferases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la réparation de l'ADN ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests d'imagerie sont-ils utiles pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests d'imagerie ne sont pas utilisés pour diagnostiquer les dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la réparation de l'ADN, des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs et des problèmes de mémoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types d'ADP ribose transferases peuvent entraîner des symptômes variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître en raison de troubles métaboliques liés aux enzymes."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines et à des radiations peut affecter l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être utiles pour les personnes à risque élevé de maladies associées."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir ces dysfonctionnements ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et enzymatique."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations ne sont pas directement liées à la prévention des dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments d'ADP-ribose peuvent être envisagés, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sur des inhibiteurs spécifiques des ADP ribose transferases sont en cours."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du type de dysfonctionnement enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils curatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la plupart des traitements visent à gérer les symptômes plutôt qu'à guérir la condition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces dysfonctionnements ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des maladies auto-immunes et des troubles neurologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent un lien entre dysfonctionnement enzymatique et maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées en fonction des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, l'exposition à des toxines et le mode de vie jouent un rôle."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur ces enzymes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut altérer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies liées peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire le risque de dysfonctionnement enzymatique."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/04/2025
Contenu vérifié selon les dernières recommandations médicales
11 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Department of Chemistry, Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
Publications dans "ADP ribose transferases" :
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205.
Publications dans "ADP ribose transferases" :
4 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California 90089, United States.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, United States.
Research Center for Liver Diseases, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
4 publications dans cette catégorie
Affiliations :
Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Department of Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Physics Frontier Center (Center for the Physics of Living Cells), University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Cristel.Camacho@utsouthwestern.edu.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. filippov@chem.leidenuniv.nl.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
UPMC Cancer Institute and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Hillman Cancer Center, 5115 Centre Avenue, Pittsburgh, PA, 15213, USA. elf115@pitt.edu.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Molecular Toxicology Group, University of Konstanz, Konstanz, Germany.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Lee.Kraus@utsouthwestern.edu.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
To investigate the potential role of EGFR, ErbBs receptors and neuregulins in human adipose tissue physiology in obesity....
Gene expression analysis in human subcutaneous (SAT) and visceral (VAT) adipose tissue in three independent cohorts [two cross-sectional (N = 150, N = 87) and one longitudinal (n = 25)], and in vitro ...
While both SAT and VAT ERBB2 and ERBB4 mRNA increased in obesity, SAT EGFR mRNA was negatively correlated with insulin resistance, but did not change in obesity. Of note, both SAT and VAT EGFR mRNA we...
This study demonstrates the association between adipose tissue ERBB2 and obesity, confirms the relevance of EGFR on human adipogenesis, and suggests a possible adipogenic role of NRG2....
Most drug target interactions for clinically approved small-molecules are non-equilibrium slow-onset, tight-binding or irreversible in nature, with pronounced element of time-dependence of inhibition....
Overexpression and mutations of the epidermal growth factor receptor (EGFR/ErbB1/HER1) and other tyrosine kinase receptors of the ErbB family (ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4) play an essential ...
Dysregulation of the ERBB/EGFR signalling pathway causes multiple types of cancer. Accordingly, ADAM17, the primary shedding enzyme that releases and activates ERBB ligands, is tightly regulated. It h...
To identify the most effective PI3K and EGFR inhibitors in HPV-positive head and neck squamous cell carcinoma (HNSCC) and investigate the efficacy of a combination of an ErbB family kinase inhibitor a...
HPV-positive HNSCC cell lines were treated with the FDA approved ErbB kinase inhibitor, Afatinib or FDA-approved PI3K inhibitor, Copanlisib, alone or in combination, and phosphorylation and total prot...
Copanlisib more effectively inhibited cell proliferation in comparison to other PI3K inhibitors tested. HPV-positive HNSCC cells differentially responded to cisplatin, Afatinib, or Copanlisib. The com...
Afatinib and Copanlisib more effectively suppress cell proliferation and survival of HPV-positive HNSCC in comparison to either treatment alone....
This phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer....
The dose-finding part enroled patients (2-<18 years) with recurrent/refractory tumours. Patients received 18 or 23 mg/m...
Of 564 patients pre-screened, 536 patients had biomarker data and 63 (12%) fulfilled ≥2 EGFR/HER2 criteria required for inclusion in the expansion part. A total of 56 patients were treated (17 in the ...
Targetable EGFR/HER2 drivers are rare in paediatric cancers. Treatment with afatinib led to a durable response (>3 years) in one patient with a glioneuronal tumour with CLIP2::EGFR fusion....
The ErbB RTKs (EGFR, HER2, HER3, and HER4) have been well-studied in cancer. EGFR, HER2, and HER3 stimulate cancer proliferation, principally by activating the phosphatidylinositol-3-kinase and extrac...
In general, human meningiomas grow slowly and have a favourable prognosis; however, some are prone to recur despite their benign histology. Therefore, knowledge of their tumour biology is essential to...
Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the...
Hepatocellular carcinoma (HCC) poses a significant global health challenge due to its poor prognosis and limited therapeutic modalities. Anoikis and ErbB signaling pathways are pivotal in cancer cell ...
This study evaluates the prognostic significance of anoikis and ErbB signaling pathways in HCC by utilizing data from The Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC),...
The single sample Gene Set Enrichment Analysis revealed a strong correlation between upregulated ErbB signaling in high anoikis-expressing tumors and poor clinical outcomes. The development of the Ano...
AERS provides a novel tool for clinical prognosis and paves the way for immune-targeted therapeutic approaches, underscoring the potential of integrated molecular profiling in enhancing treatment stra...